Pediatric Safety Evaluation of An AS-Adjuvanted H5N1 Prepandemic Candidate Vaccine in Children Aged 3-9 Years: A Phase II Study
Por:
Ballester, A, Garces-Sanchez, M, Cantarino, M, Drame, M, Bouveret, N, Gillard, P and Diez-Domingo, J
Fecha de Publicación:
01/12/2008
Resumen:
Direcciones
Ballester, A:
Generalitat Valenciana, Primary Care Pediatrician Natl Hlth Syst, Valencia, Spain
Garces-Sanchez, M:
Generalitat Valenciana, Primary Care Pediatrician Natl Hlth Syst, Valencia, Spain
Cantarino, MVP:
Generalitat Valenciana, Primary Care Pediatrician Natl Hlth Syst, Valencia, Spain
Drame, M:
GlaxoSmithKline Biol, Rixensart, Belgium
Bouveret, N:
GlaxoSmithKline Biol, Rixensart, Belgium
Gillard, P:
GlaxoSmithKline Biol, Rixensart, Belgium
Diez-Domingo, J:
Generalitat Valenciana, Primary Care Pediatrician Natl Hlth Syst, Valencia, Spain
|